Sharemaestro Newsreel

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Form 8K Adagio Medical Holdings Inc For: 11 August By Investing.com

This article announces that Adagio Medical Holdings Inc. has filed a Form 8K for August 11. The filing is related to the company's financial activities and is reported by Investing.com.

Adagio Medical reports Q2 2026 net loss of $6.7M, cash $7.7M

Adagio Medical reported a net loss of $6.7 million for Q2 2026 with no revenue, and ended the quarter with $7.7 million in cash. The company highlighted positive results from its FULCRUM-VT trial and the first patient treatment with its next-generation vCLAS Ultra catheter, …

Adagio Medical Holdings, Inc. 2026: Revenue $4.93M, EPS ($0.3) — 10-Q Summary

Adagio Medical Holdings, Inc. reported its 2026 quarterly results, with revenue reaching $4.93M and a diluted loss per share of ($0.3). The company announced significant business highlights, including completing enrollment for the FULCRUM-VT pivotal IDE study, submitting a PMA for vCLAS, and launching the …

Analysts Set Expectations for electroCore Q3 Earnings

Brookline Capital Markets adjusted its Q3 2026 EPS estimate for electroCore (NASDAQ:ECOR) to a loss of $0.27 per share. The company reported a Q2 loss of $0.33 per share, surpassing the consensus estimate, but its revenue slightly missed expectations. Despite a 10.8% stock increase, …

Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada

Vivos Therapeutics has partnered with Greenway Health to integrate its AI-powered Novare platform into Vivos' Sleep Centers of Nevada, projecting up to $9.1 million in annual value from increased patient capacity and revenue cycle improvements. This AI implementation is expected to save Vivos $1.8 …

NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification

NeuroOne Medical Technologies Corporation has announced it received ISO 13485-2016 certification, an international standard for Quality Management Systems in the Medical Device Industry. This certification allows NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain …

CeriBell (NASDAQ:CBLL) Receives "Buy" Rating from BTIG Research

BTIG Research has reaffirmed its "Buy" rating for CeriBell (NASDAQ:CBLL) and maintained a $28 price target, indicating a potential 45% upside from its current price of $19.30. Despite a wider-than-expected Q2 loss of $0.51 per share, the company's revenue exceeded estimates at $28.1 million. …

Earnings To Watch: BrainsWay Ltd (BWAY) Q2 2026 -- GF Value Sees 35% Downside

BrainsWay Ltd (BWAY) is scheduled to release its Q2 2026 earnings on August 12, 2026, with consensus estimates predicting revenues of $16.55 million and earnings of $0.07 per share. While analysts forecast an average target price of $17.67, implying a 15.32% upside, GuruFocus estimates …

HC Wainwright Cuts Earnings Estimates for Alphatec

HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for Alphatec to $0.47 from $0.59, while reiterating a "Buy" rating and a $24 price target. This revision follows Alphatec's recent quarterly earnings which met EPS expectations of $0.07 and surpassed revenue forecasts …

HC Wainwright Predicts Weaker Earnings for Apyx Medical

HC Wainwright has lowered its Q3 2026 EPS forecast for Apyx Medical (NASDAQ: APYX) to a loss of $0.07 per share from $0.06, while maintaining a Buy rating and a $7.00 price target. Despite the lowered forecast, Apyx Medical recently reported earnings that beat …

Neuronetics stock soars 15% on second quarter earnings beat

Neuronetics (NASDAQ:STIM) reported strong second-quarter results, surpassing analyst expectations with an adjusted loss per share of -$0.05 and revenue of $41.6 million. The company's stock surged over 15% in pre-market trading, driven by a 9.1% year-over-year revenue increase, primarily from its Greenbrook clinic segment. …

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) reported a Q2 loss of $0.11 per share, outperforming the Zacks Consensus Estimate of a $0.14 loss, and marking a +21.43% earnings surprise. The company's revenues reached $16.07 million, surpassing estimates by 5.92% and showing growth from $13.03 million a …

Hims & Hers Health Earnings: What To Look For From HIMS

Hims & Hers Health Earnings: What To Look For From HIMS Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here's what to expect. Hims & Hers Health missed analysts' revenue expectations last quarter, reporting revenues …

Intelligent Bio Solutions' Fingerprint Drug Study Enrolled 135

Intelligent Bio Solutions (Nasdaq: INBS) has completed its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, enrolling 135 participants across three U.S. sites. This marks the completion of all clinical data collection for its FDA 510(k) submission to detect codeine. The …

BTIG Research Cuts Tactile Systems Technology (NASDAQ:TCMD) Price Target to $39.00

BTIG Research has lowered its price target for Tactile Systems Technology (NASDAQ:TCMD) to $39.00 from $40.00, while maintaining a "buy" rating, indicating a potential upside of 33.84%. The company recently reported quarterly EPS of $0.34, exceeding the consensus estimate of $0.14, with revenue of …

HC Wainwright Boosts Earnings Estimates for Delcath Systems

HC Wainwright has increased its Q3 2026 EPS estimate for Delcath Systems (NASDAQ: DCTH) from a loss of $0.29 to a loss of $0.10, maintaining a "Buy" rating and a $32 price target. This revision follows Delcath's strong Q2 earnings report, where the company …

Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA

Neuronetics, Inc. reported a 9.1% increase in total revenue to $41.6 million for Q2 2026, driven by a 16.8% rise in Greenbrook healthcare clinic revenue. The company also significantly improved its adjusted EBITDA to $0.3 million and reduced its net loss to $3.4 million. …

Is 908 Devices Inc (MASS) Overvalued After Q2 Earnings Beat? EPS: -$11.9M; Revenue: $16.1M; GF Score: 73/100

Versa Vascular Appoints Bill Shields as Chief Executive Officer

Company Expands Series C Financing to $42M SANTA CRUZ, Calif., August 11, 2026--(BUSINESS WIRE)--Versa Vascular, Inc., a pioneering medical device company dedicated to transforming tricuspid valve disease treatment, announced the appointment of Bill Shields as Chief Executive Officer. Former Versa CEO David Hovda is …

HC Wainwright Issues Pessimistic Estimate for SENS Earnings

Abbott Laboratories price shows more positive signals - Forecast today - 11-08-2026

Abbott Laboratories (ABT) is showing positive signals, with its stock trading above its 50-day Simple Moving Average and momentum indicators generating bullish signals. The outlook remains bullish as long as support at $102.90 holds, with a target resistance level at $114.00. This forecast suggests …

908 Devices (MASS) grows H1 2026 revenue to $29.5M but records $23.8M loss

Lifeward Ltd. SEC Filing (Aug 11, 2026)

Lifeward Ltd. filed an EFFECT SEC filing on August 11, 2026, which was accepted by the SEC EDGAR. The filing is a Notice of Effectiveness for an S-3 form, with an effective date of August 10, 2026, at 4:01 P.M. The company's CIK is …

908 Devices (MASS) lifts 2026 revenue guidance after 23% Q2 sales growth

908 Devices Inc. (MASS) reported a strong Q2 2026 with revenue up 23% year-over-year to $16.1 million, driven by VipIR product demand and NIRLab contributions. The company also raised the low end of its full-year 2026 revenue guidance to $68.0–$70.0 million, representing 21%–25% growth …

908 Devices Q2 2026 earnings: Revenue rises 23% as EBITDA loss narrows

908 Devices (NASDAQ: MASS) reported Q2 2026 revenue of $16.1 million, a 23% increase year-over-year, with its adjusted EBITDA loss significantly narrowing to $1.9 million. This improvement was driven by product sales growth and the NIRLab acquisition. Despite positive operational momentum and a strong …

908 Devices Q2 revenue rises 23 percent to $16.1 million

CVRx (CVRX) ousts CRO, installs interim sales head as outlook shifts

CVRx, Inc. announced the departure of Chief Revenue Officer Robert John and the appointment of Paul Verrastro as Interim Head of Sales, effective immediately. This leadership change is attributed to a revised commercial outlook and the need to improve commercial execution. Verrastro, with over …

CV's Robert John departs as Chief Revenue Officer

Robert John, Chief Revenue Officer of CVRX, terminated his employment with the company effective August 10, 2026. He is entitled to severance pay and benefits as per his employment agreement. The reason for his departure and information regarding his replacement were not disclosed.

908 Devices Inc. 2026: Revenue $16.07M, EPS ($0.32) — 10-Q Summary

908 Devices Inc. reported Q2 2026 results with revenue of $16.07 million, a 23.3% increase year-over-year, and a narrowed net loss of ($11.89 million). Diluted loss per share improved to ($0.32) from ($0.37) in the prior-year quarter. Revenue growth was driven by higher device …

908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook

908 Devices Inc. reported strong second-quarter 2026 financial results, with revenue increasing 23% year-over-year to $16.1 million and Adjusted EBITDA loss more than halved. The company also raised the low end of its full-year 2026 revenue outlook to $68.0 million, reflecting 21% to 25% …

Teledyne agrees to acquire Varex Imaging for $1.1bn

Teledyne Technologies has entered a definitive agreement to purchase Varex Imaging in a cash transaction valued at nearly $1.1bn. Under the terms announced by both companies, Teledyne will purchase all outstanding common shares of Varex for $18.90 per share. The agreed price includes consideration …

PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Atinary Technologies Enables deeper integration of Atinary's SDLabs platform with Chemspeed automation, Bruker instruments and SciY software for closed-loop agentic AI-driven R&D BOSTON, August 11, 2026--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving …

908 Devices Secures $6M ProtectIR Order From Asia-Pacific Corrections Agency

908 Devices Inc. (Nasdaq: MASS) reported strong second-quarter 2026 financial results, with revenue increasing 23% year-over-year to $16.1 million and adjusted EBITDA loss narrowing by more than half. The company secured a $6 million ProtectIR order from an Asia-Pacific corrections agency and raised the …